Taysha Gene Therapies, Inc.
TSHAHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeTaysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic. With a market capitalization of $1.31B, it sits in small-cap territory. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome.
Market Cap
$1.31B
Beta
1.17
P/E (TTM)
—
P/E (Fwd)
-8.67
EPS (TTM)
$-0.41
EPS (Fwd)
$-0.46
ROE
-47.1%
ROA
-23.8%
Cash
$455.4M
Total Debt
$56.7M
Free CF
-$81.0M
52W Change
-17.8%
Annual Financials
Cash vs Debt
Where TSHA stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, TSHA finished 29.52% below its 150-day moving average ($5.59) and 26.63% below its 200-day moving average ($5.37). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TSHA overbought or oversold?
At the October 20, 2026 close, TSHA's RSI(14) was 27.5, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Taysha Gene Therapies, Inc. holds $455.4M in cash against $56.7M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$81.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -47.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $2.5M (2022) to $9.8M (2025), reflecting a 291% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing TSHA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.